个人中心 - 老虎社区

fann

IP属地：未知

帖子 · 45帖子 · 45
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- fannfann
  ·2021-11-28
  v
  非常抱歉，此主贴已删除
  948 评论
  2
  分享
  举报
- fannfann
  ·2021-11-24
  yes
  XPeng shares rose nearly 12% in early trading
  XPeng shares rose nearly 12% in early trading after the China-based electric vehicle maker reported
  XPeng shares rose nearly 12% in early trading
  848 评论
  5
  分享
  举报
- fannfann
  ·2021-11-13
  d
  Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.
  Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Mo
  Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.
  770 评论
  5
  分享
  举报
- fannfann
  ·2021-11-10
  h
  非常抱歉，此主贴已删除
  1,093 评论
  4
  分享
  举报
- fannfann
  ·2021-09-26
  ss
  Intel Starts Construction of Two Arizona Computer Chip Factories
  Intel broke ground on two new computer chip factories in Arizona as part of a $20 billion project to
  Intel Starts Construction of Two Arizona Computer Chip Factories
  803 1
  6
  分享
  举报
- fannfann
  ·2021-09-24
  s
  EU Will Wait To Decide On Pfizer Boosters Due To Shortage Of Safety Data
  In keeping with their more cautious approach toward approving COVID jabs,EU regulators are preparing
  EU Will Wait To Decide On Pfizer Boosters Due To Shortage Of Safety Data
  923 评论
  5
  分享
  举报
- fannfann
  ·2021-09-21
  h
  Dow Jones, Nasdaq, S&P 500 futures rally as global equities bounce back
  The dip-buyers who stepped in during the last hour of Wall Street trading yesterday are back again t
  Dow Jones, Nasdaq, S&P 500 futures rally as global equities bounce back
  535 2
  3
  分享
  举报
- fannfann
  ·2021-09-21
  d
  非常抱歉，此主贴已删除
  425 1
  2
  分享
  举报
- fannfann
  ·2021-09-16
  b
  非常抱歉，此主贴已删除
  348 评论
  1
  分享
  举报
- fannfann
  ·2021-09-13
  f
  Retail sales, Consumer Price Index: What to know this week
  Traders this week will be focused on new data on inflation and spending. Each are likely to have mod
  Retail sales, Consumer Price Index: What to know this week
  382 1
  4
  分享
  举报
暂无粉丝

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3585997214465926","uuid":"3585997214465926","gmtCreate":1622903189881,"gmtModify":1627956052914,"name":"fann","pinyin":"fann","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/c31475daaad7003b58f3385789c2f471","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":12,"headSize":126,"tweetSize":45,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.11.23","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":600939962,"gmtCreate":1638029748530,"gmtModify":1638029748620,"author":{"id":"3585997214465926","authorId":"3585997214465926","name":"fann","avatar":"https://static.tigerbbs.com/c31475daaad7003b58f3385789c2f471","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585997214465926","authorIdStr":"3585997214465926"},"themes":[],"htmlText":"v","listText":"v","text":"v","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600939962","repostId":"2186389343","repostType":4,"isVote":1,"tweetType":1,"viewCount":948,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":875729976,"gmtCreate":1637697368889,"gmtModify":1637697369016,"author":{"id":"3585997214465926","authorId":"3585997214465926","name":"fann","avatar":"https://static.tigerbbs.com/c31475daaad7003b58f3385789c2f471","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585997214465926","authorIdStr":"3585997214465926"},"themes":[],"htmlText":"yes","listText":"yes","text":"yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875729976","repostId":"1117658681","repostType":4,"repost":{"id":"1117658681","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637681053,"share":"https://www.laohunote.com/m/news/1117658681?lang=&edition=full","pubTime":"2021-11-23 23:24","market":"us","language":"en","title":"XPeng shares rose nearly 12% in early trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1117658681","media":"Tiger Newspress","summary":"XPeng shares rose nearly 12% in early trading after the China-based electric vehicle maker reported ","content":"<p>XPeng&nbsp;shares&nbsp;rose&nbsp;nearly&nbsp;12%&nbsp;in&nbsp;early&nbsp;trading&nbsp;after the China-based electric vehicle maker reported a wider-than-expected third-quarter loss but revenue that rose well above forecasts and provided an upbeat fourth-quarter outlook.<img src=\"https://static.tigerbbs.com/a8d43127b29dfc54fadaa9e23939d911\" tg-width=\"878\" tg-height=\"596\" referrerpolicy=\"no-referrer\">The net loss widened to RMB1.59 bln ($249.7 million), or RMB1.89 per American depositary share (ADS), from a loss of RMB1.15 billion a year ago. Excluding nonrecurring items, the adjusted loss per ADS came to RMB1.77, compared with the FactSet consensus of RMB1.30.</p>\n<p>Revenue jumps 187.4% to RMB5.72 billion ($895.5 million) to beat the FactSet consensus of RMB5.03 billion, as deliveries rose 199.2% to a record 25,666 vehicles, including 217.7% growth in P7 model deliveries.</p>\n<p>Gross margin improved to 14.4% from 4.6%. Looking ahead, the company expects fourth-quarter deliveries of between 34,500 and 36,500 vehicles, representing growth of 166.1% to 181.5%, and revenue between RMB7.1 billion and RMB7.5 billion, compared with the FactSet consensus of RMB6.09 billion.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>XPeng shares rose nearly 12% in early trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXPeng shares rose nearly 12% in early trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-23 23:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>XPeng&nbsp;shares&nbsp;rose&nbsp;nearly&nbsp;12%&nbsp;in&nbsp;early&nbsp;trading&nbsp;after the China-based electric vehicle maker reported a wider-than-expected third-quarter loss but revenue that rose well above forecasts and provided an upbeat fourth-quarter outlook.<img src=\"https://static.tigerbbs.com/a8d43127b29dfc54fadaa9e23939d911\" tg-width=\"878\" tg-height=\"596\" referrerpolicy=\"no-referrer\">The net loss widened to RMB1.59 bln ($249.7 million), or RMB1.89 per American depositary share (ADS), from a loss of RMB1.15 billion a year ago. Excluding nonrecurring items, the adjusted loss per ADS came to RMB1.77, compared with the FactSet consensus of RMB1.30.</p>\n<p>Revenue jumps 187.4% to RMB5.72 billion ($895.5 million) to beat the FactSet consensus of RMB5.03 billion, as deliveries rose 199.2% to a record 25,666 vehicles, including 217.7% growth in P7 model deliveries.</p>\n<p>Gross margin improved to 14.4% from 4.6%. Looking ahead, the company expects fourth-quarter deliveries of between 34,500 and 36,500 vehicles, representing growth of 166.1% to 181.5%, and revenue between RMB7.1 billion and RMB7.5 billion, compared with the FactSet consensus of RMB6.09 billion.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117658681","content_text":"XPeng shares rose nearly 12% in early trading after the China-based electric vehicle maker reported a wider-than-expected third-quarter loss but revenue that rose well above forecasts and provided an upbeat fourth-quarter outlook.The net loss widened to RMB1.59 bln ($249.7 million), or RMB1.89 per American depositary share (ADS), from a loss of RMB1.15 billion a year ago. Excluding nonrecurring items, the adjusted loss per ADS came to RMB1.77, compared with the FactSet consensus of RMB1.30.\nRevenue jumps 187.4% to RMB5.72 billion ($895.5 million) to beat the FactSet consensus of RMB5.03 billion, as deliveries rose 199.2% to a record 25,666 vehicles, including 217.7% growth in P7 model deliveries.\nGross margin improved to 14.4% from 4.6%. Looking ahead, the company expects fourth-quarter deliveries of between 34,500 and 36,500 vehicles, representing growth of 166.1% to 181.5%, and revenue between RMB7.1 billion and RMB7.5 billion, compared with the FactSet consensus of RMB6.09 billion.","news_type":1},"isVote":1,"tweetType":1,"viewCount":848,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":873030150,"gmtCreate":1636789657540,"gmtModify":1636789657680,"author":{"id":"3585997214465926","authorId":"3585997214465926","name":"fann","avatar":"https://static.tigerbbs.com/c31475daaad7003b58f3385789c2f471","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585997214465926","authorIdStr":"3585997214465926"},"themes":[],"htmlText":"d","listText":"d","text":"d","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/873030150","repostId":"1102251183","repostType":4,"repost":{"id":"1102251183","kind":"news","pubTimestamp":1636772424,"share":"https://www.laohunote.com/m/news/1102251183?lang=&edition=full","pubTime":"2021-11-13 11:00","market":"us","language":"en","title":"Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.","url":"https://stock-news.laohu8.com/highlight/detail?id=1102251183","media":"Barrons","summary":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Mo","content":"<p>Pfizer’s&nbsp;chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.</p>\n<p>“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.</p>\n<p>Two years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.</p>\n<p>Bourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.</p>\n<p>In a cover story in November 2019, <i>Barron’s</i> argued that Bourla and Dolsten could pull it off.</p>\n<p>The new antiviral data reaffirms the case for Pfizer that <i>Barron’s</i> made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.</p>\n<p>Pfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like&nbsp;Johnson &amp; Johnson&nbsp;(JNJ) and&nbsp;Eli Lilly&nbsp;(LLY).</p>\n<p>The Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.</p>\n<p>The worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.</p>\n<p>The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.</p>\n<p>While Pfizer’s Covid-19 vaccine came out of the labs of the German biotech&nbsp;BioNTech&nbsp;(BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.</p>\n<p>In the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.</p>\n<p>The antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.</p>\n<p>“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.</p>\n<p>Dolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.</p>\n<p>“[Pfizer’s] pharmaceutical R&amp;D is better than people had thought.”</p>\n<p>The protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.</p>\n<p>“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.</p>\n<p>Pfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from&nbsp;Merck&nbsp;(MRK).</p>\n<p>“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&amp;D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.</p>\n<p>Chen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.</p>\n<p>“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”</p>\n<p>That makes a bet on Pfizer a long-term play. In the meantime, the experience of&nbsp;Moderna&nbsp;(MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.</p>\n<p>Biden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”</p>\n<p>Moderna shares are down more than 40% over the past three months.</p>\n<p>As the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling <i>Barron’s</i> that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.</p>\n<p>When it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.</p>\n<p>That contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.</p>\n<p>Dolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”</p>\n<p>Such a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.</p>\n<p>An aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-13 11:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that...</p>\n\n<a href=\"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102251183","content_text":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.\n“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.\nTwo years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.\nBourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.\nIn a cover story in November 2019, Barron’s argued that Bourla and Dolsten could pull it off.\nThe new antiviral data reaffirms the case for Pfizer that Barron’s made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.\nPfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like Johnson & Johnson (JNJ) and Eli Lilly (LLY).\nThe Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.\nThe worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.\nThe success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.\nWhile Pfizer’s Covid-19 vaccine came out of the labs of the German biotech BioNTech (BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.\nIn the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.\nThe antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.\n“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.\nDolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.\n“[Pfizer’s] pharmaceutical R&D is better than people had thought.”\nThe protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.\n“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.\nPfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from Merck (MRK).\n“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.\nChen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.\n“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”\nThat makes a bet on Pfizer a long-term play. In the meantime, the experience of Moderna (MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.\nBiden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”\nModerna shares are down more than 40% over the past three months.\nAs the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling Barron’s that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.\nWhen it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.\nThat contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.\nDolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”\nSuch a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.\nAn aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.","news_type":1},"isVote":1,"tweetType":1,"viewCount":770,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":847285132,"gmtCreate":1636524401929,"gmtModify":1636524758936,"author":{"id":"3585997214465926","authorId":"3585997214465926","name":"fann","avatar":"https://static.tigerbbs.com/c31475daaad7003b58f3385789c2f471","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585997214465926","authorIdStr":"3585997214465926"},"themes":[],"htmlText":"h","listText":"h","text":"h","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/847285132","repostId":"1188205095","repostType":4,"isVote":1,"tweetType":1,"viewCount":1093,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":868517299,"gmtCreate":1632671469211,"gmtModify":1632798663240,"author":{"id":"3585997214465926","authorId":"3585997214465926","name":"fann","avatar":"https://static.tigerbbs.com/c31475daaad7003b58f3385789c2f471","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585997214465926","authorIdStr":"3585997214465926"},"themes":[],"htmlText":"ss","listText":"ss","text":"ss","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/868517299","repostId":"1142057327","repostType":4,"repost":{"id":"1142057327","kind":"news","pubTimestamp":1632643246,"share":"https://www.laohunote.com/m/news/1142057327?lang=&edition=full","pubTime":"2021-09-26 16:00","market":"us","language":"en","title":"Intel Starts Construction of Two Arizona Computer Chip Factories","url":"https://stock-news.laohu8.com/highlight/detail?id=1142057327","media":"The street","summary":"Intel broke ground on two new computer chip factories in Arizona as part of a $20 billion project to","content":"<p>Intel broke ground on two new computer chip factories in Arizona as part of a $20 billion project to help meet the high demand for semiconductors in the U.S.</p>\n<p>Intel&nbsp;(<b>INTC</b>) -Get Intel Corporation (INTC) Report&nbsp;on Friday broke ground on two new computer chip factories in Arizona as part of a $20 billion project to help&nbsp;alleviate the severe shortage of semiconductors in the U.S.</p>\n<p>The Santa Clara, Calif.-basedsemiconductor chip manufacturer'sCEO Pat Gelsinger led the project's groundbreaking ceremony at the company's Ocotillo campus in Chandler, Ariz., marking the largest private investment in the state's history.</p>\n<p>Intel expects the factories to be fully operational in 2024 to manufacture the company's most advanced process technologies.</p>\n<p>“Today’s celebration marks an important milestone as we work to boost capacity and meet the incredible demand for semiconductors: the foundational technology for the digitization of everything,\" Gelsinger said in acompany statement. \"We are ushering in a new era of innovation – for Intel, for Arizona and for the world. This $20 billion expansion will bring our total investment in Arizona to more than $50 billion since opening the site over 40 years ago.</p>\n<p>\"As the only U.S.-based leading-edge chipmaker, we are committed to building on this long-term investment and helping the United States regain semiconductor leadership,” Gelsinger said.</p>\n<p>Shares of Intel on Friday traded 0.18% higher to $54.32 after hours.</p>\n<p>Gelsinger on Thursday participated in a virtual meeting with tech company executives and Commerce Secretary Gina Raimondo to address the global semiconductor chip shortage, which has interfered with production in the high-tech, electronics and automotive industries.</p>\n<p>The two new factories, to be named Fab 52 and Fab 62, will house a total of six semiconductor fabs. The project will create over 3,000 high-tech, high-wage Intel jobs, 3,000 construction jobs and support an estimated 15,000 additional indirect jobs in the local community.</p>\n<p>Intel rival Taiwan Semiconductor Manufacturing Co.plans to buildits second U.S. chip factory also in Arizona and targets production to begin in 2024.</p>","source":"lsy1610613172068","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Intel Starts Construction of Two Arizona Computer Chip Factories</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntel Starts Construction of Two Arizona Computer Chip Factories\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-26 16:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/intel-starts-construction-of-two-arizona-computer-chip-factories><strong>The street</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Intel broke ground on two new computer chip factories in Arizona as part of a $20 billion project to help meet the high demand for semiconductors in the U.S.\nIntel (INTC) -Get Intel Corporation (INTC)...</p>\n\n<a href=\"https://www.thestreet.com/investing/intel-starts-construction-of-two-arizona-computer-chip-factories\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INTC":"英特尔"},"source_url":"https://www.thestreet.com/investing/intel-starts-construction-of-two-arizona-computer-chip-factories","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142057327","content_text":"Intel broke ground on two new computer chip factories in Arizona as part of a $20 billion project to help meet the high demand for semiconductors in the U.S.\nIntel (INTC) -Get Intel Corporation (INTC) Report on Friday broke ground on two new computer chip factories in Arizona as part of a $20 billion project to help alleviate the severe shortage of semiconductors in the U.S.\nThe Santa Clara, Calif.-basedsemiconductor chip manufacturer'sCEO Pat Gelsinger led the project's groundbreaking ceremony at the company's Ocotillo campus in Chandler, Ariz., marking the largest private investment in the state's history.\nIntel expects the factories to be fully operational in 2024 to manufacture the company's most advanced process technologies.\n“Today’s celebration marks an important milestone as we work to boost capacity and meet the incredible demand for semiconductors: the foundational technology for the digitization of everything,\" Gelsinger said in acompany statement. \"We are ushering in a new era of innovation – for Intel, for Arizona and for the world. This $20 billion expansion will bring our total investment in Arizona to more than $50 billion since opening the site over 40 years ago.\n\"As the only U.S.-based leading-edge chipmaker, we are committed to building on this long-term investment and helping the United States regain semiconductor leadership,” Gelsinger said.\nShares of Intel on Friday traded 0.18% higher to $54.32 after hours.\nGelsinger on Thursday participated in a virtual meeting with tech company executives and Commerce Secretary Gina Raimondo to address the global semiconductor chip shortage, which has interfered with production in the high-tech, electronics and automotive industries.\nThe two new factories, to be named Fab 52 and Fab 62, will house a total of six semiconductor fabs. The project will create over 3,000 high-tech, high-wage Intel jobs, 3,000 construction jobs and support an estimated 15,000 additional indirect jobs in the local community.\nIntel rival Taiwan Semiconductor Manufacturing Co.plans to buildits second U.S. chip factory also in Arizona and targets production to begin in 2024.","news_type":1},"isVote":1,"tweetType":1,"viewCount":803,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":861838061,"gmtCreate":1632479579653,"gmtModify":1632719680697,"author":{"id":"3585997214465926","authorId":"3585997214465926","name":"fann","avatar":"https://static.tigerbbs.com/c31475daaad7003b58f3385789c2f471","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585997214465926","authorIdStr":"3585997214465926"},"themes":[],"htmlText":"s","listText":"s","text":"s","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/861838061","repostId":"1147407851","repostType":4,"repost":{"id":"1147407851","kind":"news","pubTimestamp":1632476902,"share":"https://www.laohunote.com/m/news/1147407851?lang=&edition=full","pubTime":"2021-09-24 17:48","market":"us","language":"en","title":"EU Will Wait To Decide On Pfizer Boosters Due To Shortage Of Safety Data","url":"https://stock-news.laohu8.com/highlight/detail?id=1147407851","media":"zerohedge","summary":"In keeping with their more cautious approach toward approving COVID jabs,EU regulators are preparing","content":"<p>In keeping with their more cautious approach toward approving COVID jabs,<b>EU regulators are preparing to make their own decisions about whether to approve booster shots with Pfizer jab</b>s - but not until early October,Reuters reportedThursday.</p>\n<p>Reuters pointed out that<b>the upcoming review of the Pfizer booster jab would mark the European regulators' first decision about doling out booster jabs</b>in the EU.</p>\n<p>In an opinion issued earlier this month that was republished by the EMA,<b>the European Center for Disease Prevention and Control</b>- or ECDC, one of several regulators that comprises the EU's highest-level of health regulators -<b>said there was no \"urgent need\" to administer booster doses</b>to fully vaccinated individuals in the general population.</p>\n<p>But it also noted that additional doses are already being considered and doled out to the elderly, the immuno-compromised, and whatever</p>\n<p>Regardless of whatever the bloc decides,<b>it has already signed recent deals with Pfizer and BioNTech for 2.4 billion more mRNA jabs.</b></p>\n<p>The latest contract covers the supply of at least 900MM shots, which will only be needed if the EU goes ahead with expansive booster jab program and offers them to all adults 16 and up. . Over 70% of the EU's adult population has already been fully vaccinated, and the bloc has secured an ample supply of vaccines from several manufacturers.</p>\n<p>Still, as the delta wave continues to create problems for politicians around the world, they might grow increasingly desperate to force the population to get 3, 4 or even 5 jabs - despite the fact that The ECDC has said crucial data on the need and safety of boosters hasn't yet been gleaned from the studies unfurling around the world rfhr n in part because it is not yet fully clear how long vaccines protect against the virus.</p>\n<p></p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EU Will Wait To Decide On Pfizer Boosters Due To Shortage Of Safety Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEU Will Wait To Decide On Pfizer Boosters Due To Shortage Of Safety Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-24 17:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.zerohedge.com/geopolitical/eu-will-wait-decide-pfizer-boosters-due-shortage-safety-data?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+zerohedge%2Ffeed+%28zero+hedge+-+on+a+long+enough+timeline%2C+the+survival+rate+for+everyone+drops+to+zero%29><strong>zerohedge</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In keeping with their more cautious approach toward approving COVID jabs,EU regulators are preparing to make their own decisions about whether to approve booster shots with Pfizer jabs - but not until...</p>\n\n<a href=\"https://www.zerohedge.com/geopolitical/eu-will-wait-decide-pfizer-boosters-due-shortage-safety-data?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+zerohedge%2Ffeed+%28zero+hedge+-+on+a+long+enough+timeline%2C+the+survival+rate+for+everyone+drops+to+zero%29\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.zerohedge.com/geopolitical/eu-will-wait-decide-pfizer-boosters-due-shortage-safety-data?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+zerohedge%2Ffeed+%28zero+hedge+-+on+a+long+enough+timeline%2C+the+survival+rate+for+everyone+drops+to+zero%29","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1147407851","content_text":"In keeping with their more cautious approach toward approving COVID jabs,EU regulators are preparing to make their own decisions about whether to approve booster shots with Pfizer jabs - but not until early October,Reuters reportedThursday.\nReuters pointed out thatthe upcoming review of the Pfizer booster jab would mark the European regulators' first decision about doling out booster jabsin the EU.\nIn an opinion issued earlier this month that was republished by the EMA,the European Center for Disease Prevention and Control- or ECDC, one of several regulators that comprises the EU's highest-level of health regulators -said there was no \"urgent need\" to administer booster dosesto fully vaccinated individuals in the general population.\nBut it also noted that additional doses are already being considered and doled out to the elderly, the immuno-compromised, and whatever\nRegardless of whatever the bloc decides,it has already signed recent deals with Pfizer and BioNTech for 2.4 billion more mRNA jabs.\nThe latest contract covers the supply of at least 900MM shots, which will only be needed if the EU goes ahead with expansive booster jab program and offers them to all adults 16 and up. . Over 70% of the EU's adult population has already been fully vaccinated, and the bloc has secured an ample supply of vaccines from several manufacturers.\nStill, as the delta wave continues to create problems for politicians around the world, they might grow increasingly desperate to force the population to get 3, 4 or even 5 jabs - despite the fact that The ECDC has said crucial data on the need and safety of boosters hasn't yet been gleaned from the studies unfurling around the world rfhr n in part because it is not yet fully clear how long vaccines protect against the virus.","news_type":1},"isVote":1,"tweetType":1,"viewCount":923,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":860763767,"gmtCreate":1632214972359,"gmtModify":1632802025039,"author":{"id":"3585997214465926","authorId":"3585997214465926","name":"fann","avatar":"https://static.tigerbbs.com/c31475daaad7003b58f3385789c2f471","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585997214465926","authorIdStr":"3585997214465926"},"themes":[],"htmlText":"h","listText":"h","text":"h","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/860763767","repostId":"1138597781","repostType":4,"repost":{"id":"1138597781","kind":"news","pubTimestamp":1632214755,"share":"https://www.laohunote.com/m/news/1138597781?lang=&edition=full","pubTime":"2021-09-21 16:59","market":"us","language":"en","title":"Dow Jones, Nasdaq, S&P 500 futures rally as global equities bounce back","url":"https://stock-news.laohu8.com/highlight/detail?id=1138597781","media":"seekingalpha","summary":"The dip-buyers who stepped in during the last hour of Wall Street trading yesterday are back again t","content":"<p>The dip-buyers who stepped in during the last hour of Wall Street trading yesterday are back again today, pushing stocks higher around the world.</p>\n<p>S&amp;P futures(SPX), Nasdaq 100 futures(NDX:IND)and Dow Jones futures(INDU)are all up about 1%.</p>\n<p>In Asia, Japan's Nikkei(NKY:IND)is lower, catching up with trading after a holiday on Monday, but Hong Kong's Hang Seng(HSI)is up more than half a percent.</p>\n<p>In Europe, the benchmark indexes in Frankfurt, London and Paris are more than 1% higher, with the broader Stoxx 600(STOXX)up 1%.</p>\n<p>Rates are paring losses, with the 10-year Treasury yield(NYSEARCA:TBT)(NASDAQ:TLT)up 3 basis points to 1.34%.</p>\n<p>And volatility is ebbing. The S&amp;P Vix Index(VIX), also referred to as the fear gauge, is down 12% after a surge yesterday.</p>\n<p>The VIX \"traded north of 25 for the first time since May, a rise which is likely to have exacerbated some of the declines, with risk models forcing positions to be trimmed as volatility climbs, thus increasing selling, fueling a further increase in volatility; and so on, and so forth,\" Michael Brown, senior market analyst at Caxton writes.</p>\n<p><b>No Lehman moment.</b>Jitters about the impact of China's Evergrande defaulting on interest payments have eased overnight.</p>\n<p>S&amp;P Global Ratings says that a governmentbailout is unlikely unless there is systemic risk and \"far-reaching\" contagion from Evergrande.</p>\n<p>But the S&amp;P analysts also say the property company \"failing alone would unlikely result in such a scenario.\"</p>\n<p>\"The crisis at Evergrande and in the Chinese real estate sector was the catalyst (for a selloff) most people were talking about, but truth be told, the market rout we’re seeing is reflecting a wider set of risks than just Chinese property, and comes after increasing questions have been asked about whether current valuations could still be justified, with talk of a potential correction picking up,\" Deutsche Bank strategist Jim Reid writes today.</p>\n<p>\"Remember that 68% of respondents to my survey last week thought they’d be at least a 5% correction in equity markets before year end. So this has been front and center of people’s mind even if the catalyst hasn’t been clear,\" he adds.</p>\n<p><b>Time to buy?</b>Monday's tumble brought some bullish calls from Wall Street banks, where several strategists still see the path of the broader market moving up and to the right.</p>\n<p>\"The market sell-off that escalated overnight we believe is primarily driven by technical selling flows (CTAs and option hedgers) in an environment of poor liquidity, and overreaction of discretionary traders to perceived risks,” Marko Kolanovic, chief global market strategist at JPMorgan, wrote in a note yesterday. “Our fundamental thesis remains unchanged, and we see the sell-off as an opportunity to buy the dip.”</p>\n<p>From a technical perspective, Piper Sandler strategist Craig W. Johnson called this week a \"key test for the buy the dip crowd\" and that a failure to defend the S&amp;P's 50-day moving average around 4,436 \"would suggest the broader market is at risk for a deeper pullback.\"</p>\n<p>But Thomas Lee, head of research at Fundstrat, agreed with Kolanovic, saying on CNBC the time was right to look at adding to positions.</p>\n<p>\"I would look at selloffs like this, which is sort of broad-based selling, as a time to add incrementally,\"Lee said.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dow Jones, Nasdaq, S&P 500 futures rally as global equities bounce back</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDow Jones, Nasdaq, S&P 500 futures rally as global equities bounce back\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-21 16:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3741654-dow-jones-nasdaq-sp-500-futures-rally-as-global-equities-bounce-back><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The dip-buyers who stepped in during the last hour of Wall Street trading yesterday are back again today, pushing stocks higher around the world.\nS&P futures(SPX), Nasdaq 100 futures(NDX:IND)and Dow ...</p>\n\n<a href=\"https://seekingalpha.com/news/3741654-dow-jones-nasdaq-sp-500-futures-rally-as-global-equities-bounce-back\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SPY":"标普500ETF",".DJI":"道琼斯",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite"},"source_url":"https://seekingalpha.com/news/3741654-dow-jones-nasdaq-sp-500-futures-rally-as-global-equities-bounce-back","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138597781","content_text":"The dip-buyers who stepped in during the last hour of Wall Street trading yesterday are back again today, pushing stocks higher around the world.\nS&P futures(SPX), Nasdaq 100 futures(NDX:IND)and Dow Jones futures(INDU)are all up about 1%.\nIn Asia, Japan's Nikkei(NKY:IND)is lower, catching up with trading after a holiday on Monday, but Hong Kong's Hang Seng(HSI)is up more than half a percent.\nIn Europe, the benchmark indexes in Frankfurt, London and Paris are more than 1% higher, with the broader Stoxx 600(STOXX)up 1%.\nRates are paring losses, with the 10-year Treasury yield(NYSEARCA:TBT)(NASDAQ:TLT)up 3 basis points to 1.34%.\nAnd volatility is ebbing. The S&P Vix Index(VIX), also referred to as the fear gauge, is down 12% after a surge yesterday.\nThe VIX \"traded north of 25 for the first time since May, a rise which is likely to have exacerbated some of the declines, with risk models forcing positions to be trimmed as volatility climbs, thus increasing selling, fueling a further increase in volatility; and so on, and so forth,\" Michael Brown, senior market analyst at Caxton writes.\nNo Lehman moment.Jitters about the impact of China's Evergrande defaulting on interest payments have eased overnight.\nS&P Global Ratings says that a governmentbailout is unlikely unless there is systemic risk and \"far-reaching\" contagion from Evergrande.\nBut the S&P analysts also say the property company \"failing alone would unlikely result in such a scenario.\"\n\"The crisis at Evergrande and in the Chinese real estate sector was the catalyst (for a selloff) most people were talking about, but truth be told, the market rout we’re seeing is reflecting a wider set of risks than just Chinese property, and comes after increasing questions have been asked about whether current valuations could still be justified, with talk of a potential correction picking up,\" Deutsche Bank strategist Jim Reid writes today.\n\"Remember that 68% of respondents to my survey last week thought they’d be at least a 5% correction in equity markets before year end. So this has been front and center of people’s mind even if the catalyst hasn’t been clear,\" he adds.\nTime to buy?Monday's tumble brought some bullish calls from Wall Street banks, where several strategists still see the path of the broader market moving up and to the right.\n\"The market sell-off that escalated overnight we believe is primarily driven by technical selling flows (CTAs and option hedgers) in an environment of poor liquidity, and overreaction of discretionary traders to perceived risks,” Marko Kolanovic, chief global market strategist at JPMorgan, wrote in a note yesterday. “Our fundamental thesis remains unchanged, and we see the sell-off as an opportunity to buy the dip.”\nFrom a technical perspective, Piper Sandler strategist Craig W. Johnson called this week a \"key test for the buy the dip crowd\" and that a failure to defend the S&P's 50-day moving average around 4,436 \"would suggest the broader market is at risk for a deeper pullback.\"\nBut Thomas Lee, head of research at Fundstrat, agreed with Kolanovic, saying on CNBC the time was right to look at adding to positions.\n\"I would look at selloffs like this, which is sort of broad-based selling, as a time to add incrementally,\"Lee said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":535,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":860850406,"gmtCreate":1632154329105,"gmtModify":1632802448027,"author":{"id":"3585997214465926","authorId":"3585997214465926","name":"fann","avatar":"https://static.tigerbbs.com/c31475daaad7003b58f3385789c2f471","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585997214465926","authorIdStr":"3585997214465926"},"themes":[],"htmlText":"d","listText":"d","text":"d","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/860850406","repostId":"2168268325","repostType":4,"isVote":1,"tweetType":1,"viewCount":425,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":885654617,"gmtCreate":1631790309739,"gmtModify":1631889585555,"author":{"id":"3585997214465926","authorId":"3585997214465926","name":"fann","avatar":"https://static.tigerbbs.com/c31475daaad7003b58f3385789c2f471","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585997214465926","authorIdStr":"3585997214465926"},"themes":[],"htmlText":"b","listText":"b","text":"b","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/885654617","repostId":"1133643403","repostType":4,"isVote":1,"tweetType":1,"viewCount":348,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":886974284,"gmtCreate":1631547272448,"gmtModify":1631889585568,"author":{"id":"3585997214465926","authorId":"3585997214465926","name":"fann","avatar":"https://static.tigerbbs.com/c31475daaad7003b58f3385789c2f471","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585997214465926","authorIdStr":"3585997214465926"},"themes":[],"htmlText":"f","listText":"f","text":"f","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/886974284","repostId":"2166303094","repostType":4,"repost":{"id":"2166303094","kind":"news","pubTimestamp":1631488015,"share":"https://www.laohunote.com/m/news/2166303094?lang=&edition=full","pubTime":"2021-09-13 07:06","market":"us","language":"en","title":"Retail sales, Consumer Price Index: What to know this week","url":"https://stock-news.laohu8.com/highlight/detail?id=2166303094","media":"Yahoo Finance","summary":"Traders this week will be focused on new data on inflation and spending. Each are likely to have mod","content":"<p>Traders this week will be focused on new data on inflation and spending. Each are likely to have moderated last month after initial reopening surges in demand and price increases earlier this year.</p>\n<p>On the inflation front, the Labor Department's August Consumer Price Index (CPI) is set for release on Tuesday. The print is expected to decelerate on both a monthly and annual basis, suggesting the peak growth rates in prices for consumer goods and service may already have passed during this economic recovery.</p>\n<p>Consensus economists expect the broadest measure of CPI will grow 0.4% in August compared to July, and by 5.3% compared to August 2020. In July, the headline CPI grew 0.5% month-on-month and by 5.4% year-on-year, with the latter representing the fastest annual growth rate since 2008.</p>\n<p>Excluding more volatile food and energy prices, the CPI likely grew 0.3% month-on-month in August to match July's pace. However, on a year-over-year basis, the CPI excluding food and energy prices likely ticked down to a 4.2% rate, or a hair below July's 4.3% rate. That had, in turn, moderated from a 4.5% annual rate in June, which had marked the fastest rise since 1991.</p>\n<p>The multi-year highs in consumer price increases so far this year have coincided with the broadening economic recovery, as more Americans became vaccinated and were more inclined to spend. This especially drove up prices in goods and services closely tied to renewed consumer mobility.</p>\n<p>Used car and truck prices, for instances, rose at least 7.3% in each of April, May and June before decelerating sharply to an only 0.2% rise in July — suggesting an initial wave of demand was finally being unwound as consumers reacclimatized to going back out and companies' supply chains began to catch up with demand. Similar trends have been seen in prices for airline tickets, motor vehicle insurance and apparel prices, which pulled back in July after spiking earlier in late spring and early summer.</p>\n<p>Other categories of consumer prices have seen more sustained increases, especially in food and energy prices. Other services-related areas of consumption have also seen sustained rises, with consumers returning to in-person activities like dining out at bars and restaurants and leisure traveling. The CPI's \"services less energy services\" category has on a monthly basis in every month so far in 2021 except January, mostly recently at a 0.3% clip.</p>\n<p><img src=\"https://static.tigerbbs.com/b3ba3dcdb70c21ee0f288bf7cd56e371\" tg-width=\"4949\" tg-height=\"3345\" referrerpolicy=\"no-referrer\">Muhlenberg, PA - March 18: Redner's Quick Shoppe employee Julie Zezenski and Manager Pete Ostrowski work behind the counter at the Redner's Quick Shoppe on Tuckerton Road in Muhlenberg township Thursday afternoon March 18, 2021. (Photo by Ben Hasty/MediaNews Group/Reading Eagle via Getty Images)MediaNews Group/Reading Eagle via Getty Images via Getty Images</p>\n<p>\"Although the rise in global CPI inflation earlier this year was concentrated in energy and a narrow set of goods prices linked to supply constraints, the acceleration in food prices, alongside a recent pickup in services price inflation, sends a signal that pandemic-related pressures on prices are broadening,\" JPMorgan economists Nora Szentivanyi and Bruce Kasman wrote in a note last week.</p>\n<p>\"While we believe much of this pressure will prove transitory, inflation should remain elevated through early next year, as rising food and services price inflation offsets a moderation in energy and core goods price gains,\" they added.</p>\n<p>The CPI also serves as another metric pointing to the relative stickiness or transience of inflationary pressures in the recovering economy. Its outsized increases earlier this year — along with increases in the Federal Reserve's preferred inflationary gauge, core personal consumption expenditures — have suggested to some economists that the central bank might be prudent to alter its monetary policies to stave off a sustained overheating of the economy.</p>\n<p>Federal Reserve policymakers, however, have largely stuck to the conviction that inflation will prove transitory in this economy. Central bank officials like Fed Chair Jerome Powell further suggested that a premature policy move could actually backfire by cutting short the recovery in the labor market.</p>\n<p>\"The spike in inflation is so far largely the product of a relatively narrow group of goods and services that have been directly affected by the pandemic and the reopening of the economy,\" Powell said during his speech at the central bank's Jackson Hole symposium in late August.</p>\n<p>\"Some prices — for example, for hotel rooms and airplane tickets — declined sharply during the recession and have now moved back up close to pre-pandemic levels,\" he said. \"The 12-month window we use in computing inflation now captures the rebound in prices but not the initial decline, temporarily elevating reported inflation. These effects, which are adding a few tenths to measured inflation, should wash out over time.\"</p>\n<h2>Retail sales</h2>\n<p>Another closely watched economic data report out this week will be Thursday's retail sales print from the U.S. Commerce Department.</p>\n<p>Consumer spending has retreated in recent months as a boost from stimulus checks and other government support faded compared to earlier this year. In July, retail sales fell by a worse-than-expected 1.1%, which was more than three times greater than the drop expected.</p>\n<p>The August retail sales report will capture more of the impact on spending from the latest jump in coronavirus cases, with infections related to the Delta variant's spread having picked up mid-summer. Consensus economists expect to see sales fall for a back-to-back month, dropping by 0.8% for the month.</p>\n<p>Some service-related spending already slowed in July, suggesting consumers were already going out somewhat less frequently as infections mounted. Food services and drinking places sales increase by 1.7% in July, following a 2.4% monthly gain in June.</p>\n<p>The August retail sales report, however, will not capture any impact on spending related to the national expiration of enhanced unemployment benefits. Throughout the summer, about half of U.S. states had ended pandemic-era federal jobless benefits to try and incentivize unemployed individuals to return to work. The other half of states ended these benefits by Sept. 6.</p>\n<p>Future retail sales reports for September and onward may reflect slowing sales as a result of the expiration of this aid, some economists suggested.</p>\n<p>\"Spending by the unemployed, especially low-income households, has been supported by enhanced unemployment benefits,\" Rubeela Farooqi, chief economist at High Frequency Economics, wrote in a note. \"Absent this support, spending outcomes will surely be different, especially if households are less secure about job prospects going forward.\"</p>\n<h2>Economic calendar</h2>\n<ul>\n <li><p><b>Monday: </b>Monthly budget statement, August (-$302.1 billion during prior month)</p></li>\n <li><p><b>Tuesday: </b>NFIB Small Business Optimism, August (99.7 during prior month); Real Average Weekly Earnings, year-over-year, August (-0.9% during prior month); Consumer Price Index, month-over-month, August (0.4% expected, 0.5% in July); Consumer Price Index excluding food and energy, month-over-month, August (0.3% expected, 0.3% in July); Consumer Price Index, year-over-year, August (5.3% expected, 5.4% in July); Consumer Price Index excluding food and energy, year-over-year (August (4.2% expected, 4.3% in August)</p></li>\n <li><p><b>Wednesday: </b>MBA Mortgage Applications, week ended September 10 (-1.9% during prior week); Empire Manufacturing, September (20.0 expected, 18.3 during prior month); Import Price Index, month-over-month, August (0.3% expected, 0.3% in July); Industrial Production, month-over-month, August (0.6% expected, 0.9% in July); Capacity Utilization, August (76.4% in August, 76.1% in July); Manufacturing Production, August (0.4% expected, 1.4% in July)</p></li>\n <li><p><b>Thursday: </b>Retail Sales Advance, month-over-month, August (-0.8% expected, -1.1% in July); Retail Sales excluding autos and gas, August (-0.5% expected, -0.7% in July); Initial jobless claims, week ended September 11; Continuing Claims, week ended September 4; Philadelphia Fed Business Outlook Index, September (20.0 expected, 19.4 in August); Business inventories, July (0.5% expected, 0.8% in June); Total Net TIC Flows, July ($31.5 billion in June); Total Long-term TIC Flows, July ($110.9 billion in June)</p></li>\n <li><p><b>Friday: </b>University of Michigan Sentiment, September preliminary (72.7 expected, 70.3 in August)</p></li>\n</ul>\n<h2>Earnings calendar</h2>\n<ul>\n <li><p><b>Monday: </b>Oracle (ORCL) after market close</p></li>\n <li><p><b>Tuesday:</b> Lennar (LEN), FuelCell Energy (FCEL) before market open <b>&nbsp;</b></p></li>\n <li><p><b>Wednesday: </b>Weber (WEBR) before market open</p></li>\n <li><p><b>Thursday: </b><i>No notable reports scheduled for release</i></p></li>\n <li><p><b>Friday: </b><i>No notable reports scheduled for release</i></p></li>\n</ul>","source":"yahoofinance_au","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Retail sales, Consumer Price Index: What to know this week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRetail sales, Consumer Price Index: What to know this week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-13 07:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/retail-sales-consumer-price-index-what-to-know-this-week-145855567.html><strong>Yahoo Finance</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Traders this week will be focused on new data on inflation and spending. Each are likely to have moderated last month after initial reopening surges in demand and price increases earlier this year.\nOn...</p>\n\n<a href=\"https://finance.yahoo.com/news/retail-sales-consumer-price-index-what-to-know-this-week-145855567.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"WEBR":"Weber Inc.","LEN":"莱纳建筑公司","FCEL":"燃料电池能源","ORCL":"甲骨文"},"source_url":"https://finance.yahoo.com/news/retail-sales-consumer-price-index-what-to-know-this-week-145855567.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166303094","content_text":"Traders this week will be focused on new data on inflation and spending. Each are likely to have moderated last month after initial reopening surges in demand and price increases earlier this year.\nOn the inflation front, the Labor Department's August Consumer Price Index (CPI) is set for release on Tuesday. The print is expected to decelerate on both a monthly and annual basis, suggesting the peak growth rates in prices for consumer goods and service may already have passed during this economic recovery.\nConsensus economists expect the broadest measure of CPI will grow 0.4% in August compared to July, and by 5.3% compared to August 2020. In July, the headline CPI grew 0.5% month-on-month and by 5.4% year-on-year, with the latter representing the fastest annual growth rate since 2008.\nExcluding more volatile food and energy prices, the CPI likely grew 0.3% month-on-month in August to match July's pace. However, on a year-over-year basis, the CPI excluding food and energy prices likely ticked down to a 4.2% rate, or a hair below July's 4.3% rate. That had, in turn, moderated from a 4.5% annual rate in June, which had marked the fastest rise since 1991.\nThe multi-year highs in consumer price increases so far this year have coincided with the broadening economic recovery, as more Americans became vaccinated and were more inclined to spend. This especially drove up prices in goods and services closely tied to renewed consumer mobility.\nUsed car and truck prices, for instances, rose at least 7.3% in each of April, May and June before decelerating sharply to an only 0.2% rise in July — suggesting an initial wave of demand was finally being unwound as consumers reacclimatized to going back out and companies' supply chains began to catch up with demand. Similar trends have been seen in prices for airline tickets, motor vehicle insurance and apparel prices, which pulled back in July after spiking earlier in late spring and early summer.\nOther categories of consumer prices have seen more sustained increases, especially in food and energy prices. Other services-related areas of consumption have also seen sustained rises, with consumers returning to in-person activities like dining out at bars and restaurants and leisure traveling. The CPI's \"services less energy services\" category has on a monthly basis in every month so far in 2021 except January, mostly recently at a 0.3% clip.\nMuhlenberg, PA - March 18: Redner's Quick Shoppe employee Julie Zezenski and Manager Pete Ostrowski work behind the counter at the Redner's Quick Shoppe on Tuckerton Road in Muhlenberg township Thursday afternoon March 18, 2021. (Photo by Ben Hasty/MediaNews Group/Reading Eagle via Getty Images)MediaNews Group/Reading Eagle via Getty Images via Getty Images\n\"Although the rise in global CPI inflation earlier this year was concentrated in energy and a narrow set of goods prices linked to supply constraints, the acceleration in food prices, alongside a recent pickup in services price inflation, sends a signal that pandemic-related pressures on prices are broadening,\" JPMorgan economists Nora Szentivanyi and Bruce Kasman wrote in a note last week.\n\"While we believe much of this pressure will prove transitory, inflation should remain elevated through early next year, as rising food and services price inflation offsets a moderation in energy and core goods price gains,\" they added.\nThe CPI also serves as another metric pointing to the relative stickiness or transience of inflationary pressures in the recovering economy. Its outsized increases earlier this year — along with increases in the Federal Reserve's preferred inflationary gauge, core personal consumption expenditures — have suggested to some economists that the central bank might be prudent to alter its monetary policies to stave off a sustained overheating of the economy.\nFederal Reserve policymakers, however, have largely stuck to the conviction that inflation will prove transitory in this economy. Central bank officials like Fed Chair Jerome Powell further suggested that a premature policy move could actually backfire by cutting short the recovery in the labor market.\n\"The spike in inflation is so far largely the product of a relatively narrow group of goods and services that have been directly affected by the pandemic and the reopening of the economy,\" Powell said during his speech at the central bank's Jackson Hole symposium in late August.\n\"Some prices — for example, for hotel rooms and airplane tickets — declined sharply during the recession and have now moved back up close to pre-pandemic levels,\" he said. \"The 12-month window we use in computing inflation now captures the rebound in prices but not the initial decline, temporarily elevating reported inflation. These effects, which are adding a few tenths to measured inflation, should wash out over time.\"\nRetail sales\nAnother closely watched economic data report out this week will be Thursday's retail sales print from the U.S. Commerce Department.\nConsumer spending has retreated in recent months as a boost from stimulus checks and other government support faded compared to earlier this year. In July, retail sales fell by a worse-than-expected 1.1%, which was more than three times greater than the drop expected.\nThe August retail sales report will capture more of the impact on spending from the latest jump in coronavirus cases, with infections related to the Delta variant's spread having picked up mid-summer. Consensus economists expect to see sales fall for a back-to-back month, dropping by 0.8% for the month.\nSome service-related spending already slowed in July, suggesting consumers were already going out somewhat less frequently as infections mounted. Food services and drinking places sales increase by 1.7% in July, following a 2.4% monthly gain in June.\nThe August retail sales report, however, will not capture any impact on spending related to the national expiration of enhanced unemployment benefits. Throughout the summer, about half of U.S. states had ended pandemic-era federal jobless benefits to try and incentivize unemployed individuals to return to work. The other half of states ended these benefits by Sept. 6.\nFuture retail sales reports for September and onward may reflect slowing sales as a result of the expiration of this aid, some economists suggested.\n\"Spending by the unemployed, especially low-income households, has been supported by enhanced unemployment benefits,\" Rubeela Farooqi, chief economist at High Frequency Economics, wrote in a note. \"Absent this support, spending outcomes will surely be different, especially if households are less secure about job prospects going forward.\"\nEconomic calendar\n\nMonday: Monthly budget statement, August (-$302.1 billion during prior month)\nTuesday: NFIB Small Business Optimism, August (99.7 during prior month); Real Average Weekly Earnings, year-over-year, August (-0.9% during prior month); Consumer Price Index, month-over-month, August (0.4% expected, 0.5% in July); Consumer Price Index excluding food and energy, month-over-month, August (0.3% expected, 0.3% in July); Consumer Price Index, year-over-year, August (5.3% expected, 5.4% in July); Consumer Price Index excluding food and energy, year-over-year (August (4.2% expected, 4.3% in August)\nWednesday: MBA Mortgage Applications, week ended September 10 (-1.9% during prior week); Empire Manufacturing, September (20.0 expected, 18.3 during prior month); Import Price Index, month-over-month, August (0.3% expected, 0.3% in July); Industrial Production, month-over-month, August (0.6% expected, 0.9% in July); Capacity Utilization, August (76.4% in August, 76.1% in July); Manufacturing Production, August (0.4% expected, 1.4% in July)\nThursday: Retail Sales Advance, month-over-month, August (-0.8% expected, -1.1% in July); Retail Sales excluding autos and gas, August (-0.5% expected, -0.7% in July); Initial jobless claims, week ended September 11; Continuing Claims, week ended September 4; Philadelphia Fed Business Outlook Index, September (20.0 expected, 19.4 in August); Business inventories, July (0.5% expected, 0.8% in June); Total Net TIC Flows, July ($31.5 billion in June); Total Long-term TIC Flows, July ($110.9 billion in June)\nFriday: University of Michigan Sentiment, September preliminary (72.7 expected, 70.3 in August)\n\nEarnings calendar\n\nMonday: Oracle (ORCL) after market close\nTuesday: Lennar (LEN), FuelCell Energy (FCEL) before market open  \nWednesday: Weber (WEBR) before market open\nThursday: No notable reports scheduled for release\nFriday: No notable reports scheduled for release","news_type":1},"isVote":1,"tweetType":1,"viewCount":382,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"followers","isTTM":false}